CORRECTION article

Front. Pharmacol., 31 March 2022

Sec. Renal Pharmacology

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.894462

Corrigendum: The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study

  • 1. Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan

  • 2. Department of Medicine, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

  • 3. Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan

  • 4. AI Development Center, Fu Jen Catholic University, New Taipei City, Taiwan

  • 5. Division of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, New Taipei City, Taiwan

Article metrics

View details

3

Citations

899

Views

517

Downloads

In the published article, Mingchih Chen was incorrectly included as a corresponding author. The only corresponding author should be Yu-Wei Fang.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

dialysis, National Health Insurance Research Database, lipid-lowering agents, mortality, major adverse cardiovascular events

Citation

Tsai M-H, Chen M, Huang Y-C, Liou H-H and Fang Y-W (2022) Corrigendum: The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study. Front. Pharmacol. 13:894462. doi: 10.3389/fphar.2022.894462

Received

11 March 2022

Accepted

17 March 2022

Published

31 March 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Yu-Wei Fang,

†These authors have contributed equally to this work and share first authorship

This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics